Assertio Holdings (ASRT) Amortization of Deferred Charges (2019 - 2026)

Assertio Holdings' (ASRT) quarterly Amortization of Deferred Charges came in at $125000.0 in Q1 2026, up 8.7% year-on-year from $115000.0 in Q1 2025, and up 8.7% quarter-over-quarter from $115000.0 in Q1 2025.

Assertio Holdings (ASRT) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends

Assertio Holdings has disclosed Amortization of Deferred Charges across 4 years of filings, most recently posting $125000.0 for Q1 2026.

  • Amortization of Deferred Charges for Q1 2026 came in at $125000.0, up 8.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$14.2 million (down 220.43% YoY), and the FY2025 annual result was $475000.0, up 8.2% from the prior year.
  • Amortization of Deferred Charges came in at $125000.0 for Q1 2026 at Assertio Holdings, up from $115000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $125000.0 in Q1 2026 to a low of $115000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Assertio Holdings 150.94 Mn 79.37 Mn 7.22 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 125,000.00
Mar 31, 2026 125,000.00
Mar 31, 2025 115,000.00
Mar 31, 2025 115,000.00
Jun 30, 2020 125,000.00
Jun 30, 2020 125,000.00
Dec 31, 2019 -14.56 Mn
Dec 31, 2019 -14.56 Mn
Sep 30, 2019 26.10 Mn
Sep 30, 2019 26.10 Mn
Jun 30, 2019 6.06 Mn
Jun 30, 2019 6.06 Mn